Genferon Light, spray 50000 meg+1 mg/dose 100 doses

The product contains recombinant human interferon alfa-2b, produced by Escherichia coli bacterial strain, into which human interferon alfa-2b gene was introduced by genetic engineering methods. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effect.

Antiviral effect is mediated by activation of a number of intracellular enzymes that inhibit virus replication. Immunomodulatory action is primarily manifested by strengthening the cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8+ T-cells, NK-cells (natural killer cells), increased differentiation.

B-lymphocytes and their production of antibodies, activation of monocytic-macrophage system and phagocytosis, as well as increasing the expression of histocompatibility complex type I molecules, which increases the recognition of infected cells by the cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane provides their active participation in liquidation of pathological foci; besides, due to the influence of interferon the restoration of production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by the reactions of the immune system, strengthened under the influence of interferon.

Taurine helps normalize metabolic processes and tissue regeneration, has a membrane stabilizing and immunomodulatory action.

As a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to pathological processes. Taurine helps to maintain the biological activity of interferon, increasing the therapeutic effect of the drug.

Pharmacokinetics

In intranasal administration due to high concentration in the focus of infection a pronounced local antiviral and immunostimulatory effect is achieved.

The systemic absorption of the drug is insignificant – the low bioavailability of the drugs during intranasal administration is associated with the functioning of a special family of 25 proteins which are part of the nasal mucosa and which control the transport of all molecular and cellular objects passing through the mucosa.

At the same time, a certain amount of the drug enters the systemic bloodstream, due to which a systemic immunomodulatory effect is achieved.

Indications

Influenza, ARI, Flu and Cold PreventionPreventing and treating influenza and ARI in adults and children over 14 years old.

Active ingredient

Interferon alpha-2b, Taurine

Composition

1 dose of the drug contains:

active ingredients: interferon alpha-2b human recombinant* 50,000 IU, taurine 1 mg.

Auxiliary substances: disodium edetate dihydrate, glycerol, dextran 40000, polysorbate 80, sodium chloride, potassium chloride, sodium hydrophosphate dodecahydrate, potassium dihydrophosphate, peppermint oil, methyl parahydroxybenzoate, water for injection to 0.1 ml.

* The substance “Interferon alpha-2b human recombinant (rchIFN-α2b), substance-solution” contains human recombinant interferon alpha-2b (rchIFN-α2b) and excipients: sodium chloride, sodium acetate trihydrate, glacial acetic acid, water for injection.

How to take, the dosage

The drug is administered intranasally by aerosol administration of 1 dose (1 dose = 1 short pressure on the dispenser). At the first signs of the disease Genferon® Light is injected intranasally during 5 days – 1 dose (one button on the doser) into each nasal passage 3 times a day (one dose approximately equals 50 000 IU of interferon alfa, daily dose should not exceed 500 000 IU).

In case of contact with a sick person with ARVI and/or in case of hypothermia the drug is injected according to the above scheme twice a day during 5-7 days. If necessary, the preventive course is repeated.

Instructions for use of the spray: